inpefa (sotagliflozin)：Sotagliflozin (Inpefa) for heart failure
Sotagliflozin (Inpefa) for heart failure
2023年7月24日—Sotagliflozin(Inpefa)forheartfailure.MedLettDrugsTher.2023Jul24;65(1681):114-116.doi:10.58347/tml.2023.1681b.PMID:37460142;DOI ...。其他文章還包含有：「FDAUpdate」、「Inpefa(sotagliflozin)dosing,indications」、「INPEFATM(sotagliflozin)tablets」、「INPEFA®(Sotagliflozin)ReceivesPreferredFormulary...」、「NowApproved」、「Once」、「SCOREDTrial」、「SotagliflozinfortheTreatmentofHea...
查看更多 離開網站
FDA Update
https://www.acc.org
for sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2 inhibitor for the treatment of heart failure (HF), including HF with preserved ...
Inpefa (sotagliflozin) dosing, indications
https://reference.medscape.com
Medscape - Heart failure dosing for Inpefa (sotagliflozin), frequency-based adverse effects, comprehensive interactions, contraindications, ...
INPEFATM (sotagliflozin) tablets
https://www.accessdata.fda.gov
Resume INPEFA when the patient is clinically stable and has resumed oral intake [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]. 3. DOSAGE ...
INPEFA® (Sotagliflozin) Receives Preferred Formulary ...
https://finance.yahoo.com
Discovered using Lexicon's unique approach to gene science, INPEFA (sotagliflozin) is an oral inhibitor of two proteins responsible for glucose ...
Now Approved
https://www.inpefahcp.com
INPEFA™ is an inhibitor of SGLT2 and SGLT1 for patients with heart failure or patients with comorbidities and other cardiovascular risk factors.
Once
https://www.uspharmacist.com
Inpefa is classified as a dual inhibitor of both sodium-glucose cotransporter type 2 (SGLT2) and type 1 (SGLT1). Inhibiting SGLT2 diminishes ...
SCORED Trial
https://www.inpefahcp.com
INPEFA ™ is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart ...
Sotagliflozin for the Treatment of Heart Failure
https://www.clinicaltrialsaren
INPEFA™ (sotagliflozin) is a once-daily oral tablet indicated to reduce the risk of cardiovascular death, hospitalisation for heart failure ...